Innovative Foam Treatment Offers Rapid Relief for Itching and Persistent Scalp Psoriasis

A recent study conducted by the SKiN Center for Dermatology has demonstrated the effectiveness of a foam formulation of roflumilast in treating scalp and body psoriasis. This treatment not only significantly reduces the severity of lesions but also provides rapid relief from itching, a symptom that greatly impacts patients' quality of life. The clinical trial involved 432 participants aged 12 and above across the United States and Canada, who applied the roflumilast 0.3% foam once daily over an eight-week period.

The study results revealed that 66.4% of patients treated with roflumilast foam achieved clear or almost clear scalp lesions, compared to just 27.8% in the placebo group. Similarly, body lesions cleared in 45.5% of the treatment group versus 20.1% of placebo recipients. Notably, itch relief was observed within 24 hours, with a significant reduction in pruritus reported by 65.3% of patients using roflumilast at week eight, compared to 30.3% on placebo.

The treatment was generally well tolerated, although adverse events occurred more frequently in the roflumilast group (26.7%) than in the placebo group (16.6%). Serious adverse events were rare and occurred at similar rates across both groups. These findings suggest that roflumilast foam offers a promising, convenient once-daily option for patients with scalp and body psoriasis, especially for those who struggle with traditional topical treatments that may be unsuitable for hair-bearing areas.

This innovative approach could enhance adherence and improve patient outcomes, providing faster itch relief and effective lesion clearance.